An observational study in Carotid Artery Stenosis, sponsored by Cordis US Corp.. Completed at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Cordis US Corp. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Carotid Stenosis with a site in Italy — 3 open to participants now, 5 under way, none of them phase 3. Carotid Stenosis · Italy.
Among the 22 studies in Carotid Stenosis with a site in Italy, this one is the 7th largest by enrollment of the 11 observational ones that give a count, is the only one that started in 2025, is one of 11 observational ones, and was the 21st registered.
369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.
Browse Carotid Stenosis studies →3 of the 22 studies in Carotid Stenosis with a site in Italy are open now. Recruiting first, the newest first:
University of Bologna · Sites in Italy
Ages 18–150
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 199 is above the median of 176 across 161 observational studies indexed under Carotid Stenosis.
Median enrollment 150 across the 11 interventional studies, 200 across the 11 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cordis US Corp., one of the names counted as Cordis Corporation. Under that name alone:
Cordis US Corp. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Cordis Corporation has 1 study filed under Carotid Stenosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Carotid Stenosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate long-term clinical safety and performance of the PRECISE PRO RX Nitinol Stent System to treat stenotic lesions of the carotid arteries.
The REAL-PRECISE study is a multi-center, non-randomized, observational analysis of retrospective data collected on subjects treated with PRECISE PRO Rx Nitinol Stent System. The purpose of this study is to evaluate the long-term (5-year) safety and performance of PRECISE PRO Rx Nitinol Stent System in subjects with stenotic lesions of the carotid arteries. The study is conducted in up to 15 European study sites in approximately 3 countries with high volume use of PRECISE PRO Rx. The enrollment and data collection takes approximately 4-6 months.
Subjects treated with the PRECISE PRO Rx Nitinol Stent System according to the Instructions for Use for treatment of carotid artery stenosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
NOTE: This is a RETROSPECTIVE study designed to collect outcomes on subjects who were already treated with the study device.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects treated with the PRECISE PRO Rx Nitinol Stent System according to the Instructions for Use for treatment of carotid artery stenosis
Device: PRECISE PRO Rx Nitinol Stent System
The Cordis PRECISE PRO Rx Nitinol Stent System is a single-use device consisting of an endovascular stent and sheath delivery system, intended to deliver a self-expanding endovascular stent to the carotid artery(ies). The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The Cordis PRECISE PRO Rx Nitinol Stent System is indicated for use in patients with stenotic lesions of the carotid artery(ies).
Performance Endpoint - Technical Success
Achievement of a final residual stenosis of \<30% at the target lesion using any percutaneous method at the conclusion of the index procedure
Time frame: At the conclusion of the index procedure
Performance Endpoint - Target Lesion Revascularization (TLR) at 12 months
A repeat revascularization procedure performed at the original treatment site due to restenosis of ≥50% at the target lesion (as confirmed by quantitative angiography) in the presence of symptoms or ≥80% in the absence of symptoms
Time frame: At 12 months
Safety Endpoint - All-Cause Mortality
All site-reported events of all-cause mortality
Time frame: Through 5 years
Safety Endpoint - Myocardial Infarction
All site-reported events of myocardial infarction
Time frame: Through 5 years.
Safety Endpoint - Major Stroke
A major stroke is defined as a cerebrovascular accident
Time frame: Through 5 years
Safety Endpoint - Minor Stroke
A minor stroke is defined as a transient ischemic attack
Time frame: Through 5 years
Safety Endpoint - Thrombosis
All site-reported events of thrombosis
Time frame: Through 5 years
Stent Patency
The stent patency is defined as 30% stenosis immediately post-stent placement and \< 50% stenosis long-term
Time frame: Through 5 years
All adverse events
All adverse events reported by sites
Time frame: Through 5 years
In-Stent Restenosis (ISR)
All site-reported events of In-Stent Restenosis (ISR) evaluated through any imaging assessment performed
Time frame: Through 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Feb 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.